Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone

Open access
Lolli, Cristian, Caffo, Orazio, Scarpi, Emanuela, Aieta, Michele, Conteduca, Vincenza, Maines, Francesca, Bianchi, Emanuela, Massari, Francesco, Veccia, Antonello, Chiuri, Vincenzo E., Facchini, Gaetano, De Giorgi, Ugo·2016·Frontiers in Pharmacology

Abstract

Background: A systemic immune-inflammation index (SII) based on neutrophil (N), lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid tumors. The aim of this study is to evaluate the prognostic role of SII in mCRPC patients treated with abiraterone post docetaxel. Patients and Methods: We retrospectively reviewed consecutive mCRPC patients treated with abiraterone after docetaxel in our Institutions. X-tile 3.6.1 software, cut-off values of SII, NLR defined as N/L and PLR as P/L. Overall survival (OS) and their 95% Confidence Intervals (95% CI) was estimated by the Kaplan-Meier method and compared with the log-rank test. The impact of SII, PLR and NLR on OS was evaluated by Cox regression analyses and on PSA response rates were evaluated by binary logistic regression. Results: A total of 230 mCRPC patients treated abiraterone were included. SII ≥535, NLR ≥3 and PLR ≥210 were considered as elevated levels (high risk groups. The median OS was 17.3 months, 21.8 months in SII <535 group and 14.7 months in SII ≥535 (p < 0.0001). At univariate analysis ECOG performance status, previous enzalutamide, visceral metastases, SII, NLR and PLR predicted OS. In multivariate analysis, ECOG performance status, previous enzalutamide, visceral metastases, SII and NLR remained significant predictors of OS (HR = 5.08, p < 0.0001; HR = 2.12, p = 0.009, HR = 1.77, 95% p = 0.012; HR = 1.80, p = 0.002; and HR = 1.90, p = 0.001, respectively), whereas, PLR showed a borderline ability only (HR = 1.41, p = 0.068). Conclusion: SII and NLR might represent an early and easy prognostic marker in mCRPC patients treated with abiraterone. Further studies are needed to better define their impact and role in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2016.00376

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 188

Metadata

Authors
Lolli, C., Caffo, O., Scarpi, E., Aieta, M., Conteduca, V., Maines, F., Bianchi, E., Massari, F., Veccia, A., Chiuri, V. E., Facchini, G., & De Giorgi, U.
Venue
Frontiers in Pharmacology
Published
2016-10-13
Volume
7
Pages
376-376
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2530956228
Cited by
188
References
6
FWCI
8.19
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. https://app.cochat.ai/papers/10.3389/fphar.2016.00376
The paper
Lolli, C., Caffo, O., Scarpi, E., Aieta, M., Conteduca, V., Maines, F., Bianchi, E., Massari, F., Veccia, A., Chiuri, V. E., Facchini, G., & De Giorgi, U. (2016). Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2016.00376

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.